NR4A1 and breast carcinoma: As we intend to apply our strategy to target breast cancer via CD44, we focused our attention on the detection of this biomarker on the cell membrane of two different breast cancer (BC) cell lines: MCF-7, representing the hormone receptor-positive (HR+) breast cancer subtype, and MBA-MB-231, corresponding to TNBC.